DATASHEET - Medsafe
CCDS180124v007 Page 1 of 12 MOTILIUM(180601)DDS MOTILIUM® domperidone. DATASHEET 1. PRODUCT NAME Motilium 10 mg film-coated tablets 2. QUALITATIVE AND Q UANTITATIVE COMPOSITION
Download DATASHEET - Medsafe
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
Presentation, Advantan presentation uses, Advantan, Uses, Methylprednisolone aceponate, Methylprednisolone, Aceponate
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Draft, Good, Practices, Manufacturing, Edition, Edition draft, Good manufacturing practice
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
HIGHLIGHTS OF PRESCRIBING INFORMATION ... - …
www.aloxi.com1 INDICATIONS AND USAGE 1.1 Chemotherapy-Induced Nausea and Vomiting in Adults ALOXI is indicated for:
DRUG NAME: Crizotinib - BC Cancer
www.bccancer.bc.caCrizotinib BC Cancer Agency Cancer Drug Manual© Page 2 of 6 Crizotinib Developed: 1 April 2014 Revised: 1 September 2014. Caution: • vision disorders. have been reported; ability to drive or operate machinery may be compromised.
DRUG NAME: Degarelix - BC Cancer
www.bccancer.bc.caDegarelix BC Cancer Agency Cancer Drug Manual© Page 1 of 6 Degarelix Developed: 1 February 2015 Revised: DRUG NAME: Degarelix SYNONYM(S): degarelix acetate …
DRUG INDUCED QT PROLONGATION - GGC …
www.ggcprescribing.org.ukIssue 21, December 2012 Produced by NHS Greater Glasgow and Clyde Medicines Information Service . DRUG INDUCED QT PROLONGATION Prolongation of the QT interval can lead to a
Drug, Induced, Drug induced qt prolongation, Prolongation, Drug induced qt prolongation prolongation
DATASHEET - Medsafe Home Page
www.medsafe.govt.nznozinan-ccsiv1-dsv11-18jan17 1 DATASHEET NOZINAN ® NAME OF THE MEDICINE Levomepromazine hydrochloride 25mg/mLinjection. Levomepromazine maleate …
TQT Studies: Their Impact on Drug Development …
www.richmondpharmacology.comTQT Studies: Their Impact on Drug Development and the Key Elements of a Successful TQT Study Asif Naseem, Keith Berelowitz, Ulrike Lorch, Radivoj Arezina and Jorg Taubel
QT PROLONGATION and TORSADES DE POINTES: …
www.rxfiles.caThe Rx Files: Q&A Summary Mar, 2005 S. Downey BSP, B. Jensen BSP, L.Regier BSP, BA PROMOTING OPTIMAL DRUG THERAPY www.RxFiles.ca QT PROLONGATION and TORSADES DE POINTES: DRUGS and SUDDEN DEATH
Drug, Prolongation, Qt prolongation and torsades de pointes, Torsades, Pointes
ECG Manifestations: The Poisoned Patient
www.ubccriticalcaremedicine.caECG Manifestations: The Poisoned Patient Christopher P. Holstege, MD*, David L. Eldridge, MD, Adam K. Rowden, DO Division of Medical Toxicology, Department of Emergency Medicine,
Patients, Ecg manifestations, Manifestations, The poisoned patient, Poisoned